Nicotinic ligands modulate ethanol-induced dopamine function in mice

Pharmacology

Volumn 86, Issue 3, 2010, Pages 168-173

  Sajja, Ravi K ^a   Dwivedi, Chandradhar ^a   Rahman, Shafiqur ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Cytisine; Dopamine; Ethanol; Lobeline; Nicotinic receptor; Ventral striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ALCOHOL; CYTISINE; DOPAMINE; LOBELINE; NICOTINIC RECEPTOR;

ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3,4-DIHYDROXYPHENYLACETIC ACID; ALKALOIDS; ANIMALS; AZOCINES; BASAL GANGLIA; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; LIGANDS; LOBELINE; MALE; MECAMYLAMINE; MICE; MICE, INBRED C57BL; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; QUINOLIZINES; RECEPTORS, NICOTINIC;

EID: 77955527092     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317063     Document Type: Article

References (29)

1. Di Chiar a G, Ba ssareo V: Rewa rd sy stem a nd addiction: what dopamine does and doesn't do. Curr Opin Pharmacol 2007; 7:69-76.
2. Koob GF, Volkow ND: Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35: 217-238.
3. Larsson A, Engel JA: Neurochemical and behavioral studies on ethanol and nicotine interactions. Neurosci Biobehav Rev 2004; 27: 713-720.
4. Wonnacott S, Sidhpura N, Balfour DJ: Nicotine: from molecular mechanisms to behaviour. Curr Opin Pharmacol 2005; 5: 53-59.
5. Gotti C, Riganti S, Clementi F: Brain neuro-nal nicotinic receptors as new targets for drug discovery. Curr Pharm Des 2006; 12: 407-428.
6. Rahman S, Lopez-Hernandez GY, Corrigall WA, Papke RL: Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction. CNS Neurol Disord Drug Targets 2008; 7:422-441.
7. Ericson M, Löf E, Stomberg R, Söderpalm B: The smoking cessation medication vareni-cline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther 2009; 329: 225-230.
8. Tizabi Y, Bai L, Copeland RL Jr, Taylor RE: Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcoholism 2007; 42:413-416.
9. Kamens HM, Andersen J, Picciotto MR: Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl) 2010, E-pub ahead of print.
10. Kuzmin A, Jerlhag E, Liljequist S: Effects of subunit selective nAChR receptors on oper-ant self-administration and relapse-like eth-anol-drinking behavior. Psychopharmacol-ogy (Berl) 2009; 203:99-108.
11. Janhunen S, Ahtee L: Differential nicotinic regulation of the nigrostriatal and mesolim-bic dopaminergic pathways: implications for drug development. Neurosci Biobehav Rev 2007; 31:287-314.
12. Klink R, De Kerchove d'Exaerde A, Zoli M, Changeux JP: Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neu-rosci 2001; 21:1452-1463.
13. Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT: The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibro-mide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens. Eur J Pharmacol 2008; 601:103-105.
14. Damaj MI, Patrick GS, Creasy KR, Martin BR: Pharmacology of lobeline, a nicotinic receptor ligand. J Pharmacol Exp Ther 1997; 282:410-419.
15. Dwoskin LP, Crooks PA: A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Bio-chem Pharmacol 2002; 63:89-98.
16. 3H]dopamine uptake. J Pharmacol Exp Ther 1997; 280: 1432-1444.
17. Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, Dwoskin LP: Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther 2004; 310: 1035-1045.
18. Harrod SB, Dwoskin LP, Crooks PA, Klebaur JE, Bardo MT: Lobeline attenuates d-meth-amphetamine self-administration in rats. J Pharmacol Exp Ther 2001; 298:172-179.
19. Benwell ME, Balfour DJ: The influence of lo-beline on nucleus accumbens dopamine and locomotor responses to nicotine in nicotine-pretreated rats. Br J Pharmacol 1998; 125: 1115-1119.
20. Miller DK, Lever JR, Rodvelt KR, Baskett JA, Will MJ, Kracke GR: Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend 2007; 89: 282-291.
21. Bell RL, Eiler BJ 2nd, Cook JB, Rahman S: Nicotinic receptor ligands reduce ethanol intake by high alcohol-drinking HAD-2 rats. Alcohol 2009; 43: 581-592.
22. Farook JM, Lewis B, Gaddis JG, Littleton JM, Barron S: Lobeline, a nicotinic partial agonist, attenuates alcohol consumption and preference in male C57BL/6J mice. Physiol Behav 2009; 97:503-506.
23. Papke RL, Heinemann SF: Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit. Mol Pharmacol 1994; 45:142-149.
24. Minuer YS, Somenzi O, Picciotto MR: Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepres-sant-like properties in male C57BL/6J mice. Neuropharmacology 2007;52:1256-1262.
25. Tutka P, Zatöski W: Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol Rep 2006; 53: 777-798.
26. Hendrickson LM, Zhao-Shea R, Tapper AR: Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. Psy-chopharmacology (Berl) 2009; 204: 563-572.
27. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE: Varenicline, an 04-2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 2007; 104: 12518-12523.
28. 2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 2009; 78: 813-824.
29. 2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48: 3474-3477. (Pubitemid 40664098)